Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Nine brokerages give Eupraxia Pharmaceuticals a consensus “Moderate Buy” rating, with an average 12-month price target of $18.00 versus the stock’s recent $7.36 price.
• Institutional ownership increased: Several hedge funds initiated positions during the first quarter, while Affinity Asset Advisors raised its holdings by 429.7% to 1.59 million shares.
• The company remains in clinical-stage development: Eupraxia focuses on therapies for autoimmune and inflammatory diseases, with its lead candidate in Phase 1 trials for systemic lupus erythematosus; it reported quarterly EPS of $(0.23), beating estimates by $0.02.

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $18.00.

A number of brokerages recently issued reports on EPRX. HC Wainwright restated a "buy" rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research note on Monday, May 4th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Thursday, May 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Finally, Stifel Nicolaus initiated coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They set a "buy" rating and a $25.00 price target on the stock.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP bought a new position in shares of Eupraxia Pharmaceuticals in the first quarter worth $5,137,000. Redmile Group LLC bought a new stake in shares of Eupraxia Pharmaceuticals during the 1st quarter valued at $5,068,000. Rubric Capital Management LP bought a new stake in shares of Eupraxia Pharmaceuticals during the 1st quarter valued at $5,004,000. DV Trading LLC purchased a new stake in Eupraxia Pharmaceuticals during the 1st quarter worth about $1,998,000. Finally, Affinity Asset Advisors LLC lifted its holdings in Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company's stock worth $11,504,000 after purchasing an additional 1,289,005 shares in the last quarter.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ:EPRX opened at $7.36 on Friday. The company has a market capitalization of $478.55 million, a P/E ratio of -7.22 and a beta of 1.08. The business has a fifty day simple moving average of $6.60 and a two-hundred day simple moving average of $7.04. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. Eupraxia Pharmaceuticals has a 1 year low of $5.12 and a 1 year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.02. On average, analysts expect that Eupraxia Pharmaceuticals will post -0.87 earnings per share for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source